144.00
price up icon0.23%   0.33
after-market After Hours: 144.00
loading
Neurocrine Biosciences Inc stock is traded at $144.00, with a volume of 636.13K. It is up +0.23% in the last 24 hours and down -1.82% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$143.67
Open:
$143.6
24h Volume:
636.13K
Relative Volume:
0.72
Market Cap:
$14.28B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.81
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+2.79%
1M Performance:
-1.82%
6M Performance:
+36.16%
1Y Performance:
+24.65%
1-Day Range:
Value
$142.20
$144.42
1-Week Range:
Value
$138.78
$144.65
52-Week Range:
Value
$84.23
$154.61

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
144.00 14.25B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
145.94 64.88B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.01 44.40B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.25 41.72B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.95 21.82B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
418.58 19.28B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-21-25 Initiated Citigroup Buy
Jul-21-25 Initiated Truist Buy
Jul-10-25 Initiated Goldman Buy
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
01:21 AM

How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Levels & Verified Chart Pattern Signals - newser.com

01:21 AM
pulisher
12:31 PM

Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levels2025 Biggest Moves & Short-Term Trading Alerts - newser.com

12:31 PM
pulisher
12:00 PM

Can Neurocrine Biosciences Inc. stock sustain revenue growth2025 Buyback Activity & Free Long-Term Investment Growth Plans - newser.com

12:00 PM
pulisher
Oct 25, 2025

Short interest data insights for Neurocrine Biosciences Inc.Weekly Loss Report & Risk Managed Investment Strategies - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsPortfolio Update Summary & Verified High Yield Trade Plans - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Is Neurocrine Biosciences Inc a good long term investmentShort-Term Trading Alerts & You’ll Thank Yourself in 6 Months - earlytimes.in

Oct 25, 2025
pulisher
Oct 25, 2025

Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikes2025 Key Highlights & Consistent Return Investment Signals - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

What moving averages say about Neurocrine Biosciences Inc.2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 - Yahoo Finance

Oct 25, 2025
pulisher
Oct 25, 2025

Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo

Oct 25, 2025
pulisher
Oct 24, 2025

Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice - Yahoo Finance

Oct 24, 2025
pulisher
Oct 23, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Did Positive KINECT 4 Data Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - simplywall.st

Oct 22, 2025
pulisher
Oct 21, 2025

Full technical analysis of Neurocrine Biosciences Inc. stockMarket Weekly Review & Low Risk Growth Stock Ideas - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Can Neurocrine Biosciences Inc. stock maintain growth trajectory2025 Analyst Calls & Daily Technical Forecast Reports - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

What analysts say about Neurocrine Biosciences Inc NB3 stockBollinger Bands Signals & Daily Tips From Top Market Analysts - earlytimes.in

Oct 21, 2025
pulisher
Oct 21, 2025

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Citigroup Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - Nasdaq

Oct 21, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.58
price down icon 0.27%
$10.35
price up icon 0.39%
$22.05
price up icon 1.29%
$48.78
price up icon 0.60%
$418.58
price down icon 1.79%
Cap:     |  Volume (24h):